abstract |
The invention relates to new crystalline forms of the meglumine salt 2 - ((1R, 4R) -4- (4- (5- (benzo [d] oxazol-2-ylamino) pyridin-2-yl) phenyl) cyclohexyl) acetic acid of the formula ( I) and their use in the treatment or prevention of a condition or disorder associated with DGAT1 activity in animals, especially humans. |